About dose.wiki
An open encyclopedic database for the study of psychopharmacology
Mission
dose.wiki exists to serve as a modern, open-source, and comprehensive encyclopedic database for the study of psychopharmacology. It was created because the various overlapping subcultures of the online psychonaut, psychedelic, and drug nerd communities have been sorely lacking a resource of this kind for far too long—a website that is up to modern web standards and is fully open source, with easily accessible and reusable datasets.
The datasets for the Substance Index, Subjective Effect Index, and Trip Report Index are all available for download on the Open Data tab, and the licensing for each facet of our database is available on our licensing and reuse page. So, if you want to use our database within any of your projects, or even integrate it into your own substance encyclopedia website, we strongly encourage you to do so!
Our hope for this platform is that it can serve not just as a convenient and helpful harm reduction resource for the average psychonaut, but also as a comprehensive database of consistently structured data that is easy for researchers and developers to build on and fork from—with all of it falling under an open source license.
It's 202X+ already and we are living in the future; we think it's about time that this knowledge stopped being gate kept behind stagnating platforms and disparate APIs. The information necessary to create an online psychoactive substance encyclopedia is now irreversibly commoditized, and there is no going back.
Documentation
Downloads
JSON, refreshed nightly from the live database. Reuse terms vary by dataset — see License & reuse.
Molecule art pack
All 267 substance structures as consistent SVGs in two colourways — dose.wiki brand and standard textbook element colours — plus a SMILES + metadata manifest. Generated from SMILES with RDKit.
Archival SubstanceIndex.json preview
1{
2 "id": 5,
3 "title": "1cP-MiPLA",
4 "priority": "high",
5 "index_categories": [],
6 "identification": {
7 "common_name": "1cP-MiPLA",
8 "substitutive_name": "1-Cyclopropionyl-N-methyl-N-isopropyllysergamide",
9 "iupac_name": "(6aR,9R)-4-(cyclopropanecarbonyl)-N,7-dimethyl-N-propan-2-yl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide",
10 "alternative_names": [
11 "1cP-MIPLA",
12 "Lamide (parent compound)"
13 ],
14 "smiles": "CN1C[C@@H](C=C2[C@H]1Cc1cn(c3c1c2ccc3)C(=O)C1CC1)C(=O)N(C(C)C)C",
15 "inchi_key": "",
16 "cas_number": "",
17 "molecular_formula": "C24H29N3O2",
18 "molecular_weight": "391.506 g/mol",
19 "skeletal_structure_image": "",
20 "botanical_name": ""
21 },
22 "classification": {
23 "psychoactive_class": [
24 "Psychedelic"
25 ],
26 "chemical_class": [
27 "Lysergamide"
28 ]
29 },
30 "summary": "1cP-MiPLA is a semisynthetic psychedelic of the lysergamide class that first emerged as a novel designer drug around 2020.[cite:url-aipsin-com-562] It is a structural analog of MiPLA and is suspected to act as a prodrug for that compound, though insufficient data currently exists to confirm this relationship.[cite:doi-10-1007-s11419-023-00661-1] As a research chemical with limited documented human use, its safety profile and pharmacological properties remain poorly characterized.",
31 "dosage": {
32 "routes": [
33 {
34 "route": "oral",
35 "bioavailability": "",
36 "bioavailability_notes": "",
37 "dose_ranges": {
38 "threshold": {
39 "min": 50,
40 "max": null,
41 "unit": "µg"
42 },
43 "light": {
44 "min": 100,
45 "max": 150,
46 "unit": "µg"
47 },
48 "moderate": {
49 "min": 150,
50 "max": 200,
51 "unit": "µg"
52 },
53 "strong": {
54 "min": 200,
55 "max": 250,
56 "unit": "µg"
57 },
58 "heavy": {
59 "min": 300,
60 "max": null,
61 "unit": "µg"
62 }
63 },
64 "notes": "The spacing between threshold and light dose ranges is unusually wide, reflecting the scarcity of reliable dosing data for this recently emerged compound.",
65 "reference_ids": []
66 }
67 ],
68 "plateau_dosing": null
69 },
70 "duration": {
71 "routes": [
72 {
73 "route": "oral",
74 "half_life": "",
75 "half_life_notes": "",
76 "stages": {
77 "onset": {
78 "min": 20,
79 "max": 40,
80 "unit": "minutes"
81 },
82 "come_up": {
83 "min": 45,
84 "max": 90,
85 "unit": "minutes"
86 },
87 "peak": {
88 "min": 1,
89 "max": 2,
90 "unit": "hours"
91 },
92 "offset": {
93 "min": 1,
94 "max": 2,
95 "unit": "hours"
96 },
97 "after_effects": {
98 "min": null,
99 "max": null,
100 "unit": "hours"
101 },
102 "total_duration": {
103 "min": 4,
104 "max": 6,
105 "unit": "hours"
106 }
107 },
108 "reference_ids": []
109 }
110 ]
111 },
112 "subjective_effects": {
113 "notes": {
114 "overview": "1cP-MiPLA is believed to act as a prodrug for MiPLA, and its subjective effects are correspondingly reported to closely mirror those of its parent compound. The experience is that of a classic lysergamide psychedelic in the vein of LSD, though it is generally described as gentler, shorter-lasting, and less mentally demanding than LSD itself. Formal documentation of this compound remains minimal, and its effect profile is inferred largely from user reports and its relationship to MiPLA.",
115 "sensory": "Visual effects follow the typical lysergamide pattern of color enhancement, flowing distortions, and geometric patterning, though they are commonly reported as softer and less forceful than those of LSD at comparable doses.",
116 "cognitive": "The headspace is often characterized as relatively clear and easygoing, with euphoria and an altered sense of time, and with less of the anxiety and cognitive intensity associated with LSD.",
117 "physical": "The body load is generally described as light, consisting primarily of mild stimulation alongside standard serotonergic psychedelic signs such as pupil dilation."
118 },
119 "sensory": {
120 "visual": {
121 "note": "Visual effects are characteristic of lysergamide psychedelics but are typically milder than those of LSD at equivalent doses.",
122 "subcategories": {
123 "distortions": {
124 "note": "",
125 "effects": [
126 {
127 "name": "Drifting",
128 "description": ""
129 },
130 {
131 "name": "Tracers",
132 "description": ""
133 }
134 ]
135 },
136 "enhancements": {
137 "note": "",
138 "effects": [
139 {
140 "name": "Color enhancement",
141 "description": ""
142 }
143 ]
144 },
145 "geometry": {
146 "note": "",
147 "effects": [
148 {
149 "name": "Geometry",
150 "description": "Geometric patterning is present but generally less intricate and intense than that produced by LSD."
151 }
152 ]
153 }
154 }
155 },
156 "auditory": {
157 "note": "",
158 "subcategories": {}
159 },
160 "tactile": {
161 "note": "",
162 "subcategories": {}
163 },
164 "olfactory": {
165 "note": "",
166 "subcategories": {}
167 },
168 "gustatory": {
169 "note": "",
170 "subcategories": {}
171 },
172 "multisensory": {
173 "note": "",
174 "subcategories": {}
175 }
176 },
177 "cognitive": {
178 "emotional": {
179 "note": "",
180 "effects": [
181 {
182 "name": "Euphoria",
183 "description": ""
184 }
185 ]
186 },
187 "perception": {
188 "note": "",
189 "effects": [
190 {
191 "name": "Time distortion",
192 "description": ""
193 }
194 ]
195 }
196 },
197 "physical": {
198 "neurological": {
199 "note": "",
200 "effects": [
201 {
202 "name": "Pupil dilation",
203 "description": ""
204 }
205 ]
206 },
207 "stimulation": {
208 "note": "",
209 "effects": [
210 {
211 "name": "Stimulation",
212 "description": "Mild and less pronounced than the stimulation associated with LSD."
213 }
214 ]
215 }
216 },
217 "attribution": {
218 "author": "dose.wiki AI editorial pipeline",
219 "text": "This section was synthesized from the article's collected source material by dose.wiki's AI editorial pipeline.",
220 "url": ""
221 }
222 },
223 "comparisons": [],
224 "pharmacology": {
225 "pharmacodynamics": "Direct receptor-binding and functional-activity data have not been reported for 1cP-MiPLA. The available primary study identified the substance in sheet products but did not assess its biological activity.[cite:doi-10-1007-s11419-023-00661-1]",
226 "binding_sites": [],
227 "pharmacokinetics": "No substance-specific metabolic pathway has been reported for 1cP-MiPLA.[cite:doi-10-1007-s11419-023-00661-1] Conversion to MiPLA remains a hypothesis by analogy with other N1-acyl lysergamides: conversion of 1cP-LSD to LSD has been demonstrated in human serum, but conversion of 1cP-MiPLA to MiPLA has not.[cite:doi-10-1002-dta-2789]",
228 "metabolites": []
229 },
230 "interactions": {
231 "dangerous": [
232 "Lithium (There are a large number of reports indicating a high seizure and psychosis risk from this combination.)"
233 ],
234 "unsafe": [
235 "Tramadol (Tramadol is well known to lower seizure threshold and psychedelics also cause occasional seizures.)"
236 ],
237 "caution": [
238 "Amphetamines (Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences)",
239 "Cannabis (Cannabis has an unexpectedly strong and somewhat unpredictable synergy with psychedelics.)",
240 "Cocaine (Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences)",
241 "Diphenhydramine (At 25-50mg, DPH may assist with side effects of the LSD such as nausea and anxiety. At higher dosages, the combination of a deliriant (DPH) and LSD is cautioned against. LSD is likely to increase the deliriant and negative effects of DPH, in addition to increasing the risk of severe injury and mental trauma. LSD and DPH at recreational dosages have additional cardiac concerns such as vasoconstriction, tachycardia, hypertension, which in combination may be exacerbated.)",
242 "Mephedrone (The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops, in addition to the possible negative side effects of coming down from said stimulant while on a psychedelic. In extreme cases, stimulants, especially in combination can result in severe vasoconstriction, tachycardia, hypertension, and heart failure.)",
243 "Pregabalin (Caution should be given due to LSD’s stimulating effects and pregabalin’s seizure concerns at higher dosages. Pregabalin may reduce the vasoconstriction, anxiety, and other side effects of LSD. Additionally, Pregabalin may increase LSD’s inhibition and risk of injury.)"
244 ]
245 },
246 "reagent_testing": {},
247 "tolerance": {
248 "full_tolerance": "Tolerance to the effects of 1cP-MiPLA develops almost immediately following ingestion, consistent with the rapid tolerance pattern observed with other lysergamide psychedelics.",
249 "half_tolerance": "Approximately 5-7 days after use, tolerance is estimated to decrease to roughly half of its peak level.",
250 "baseline_tolerance": "Complete return to baseline tolerance typically requires around 14 days of abstinence from 1cP-MiPLA and other serotonergic psychedelics.",
251 "cross_tolerance": [
252 "Serotonergic psychedelics (LSD, psilocybin, mescaline, DMT)",
253 "Other lysergamides"
254 ]
255 },
256 "harm_potential": {
257 "addiction": {
258 "psychological": {
259 "level": "extremely_low",
260 "description": "Assumed to be non-habit-forming based on its similarity to LSD[cite:pmid-26841800]; the desire to use may actually decrease with repeated administration. No formal studies have been conducted."
261 },
262 "physical_dependence": {
263 "level": "extremely_low",
264 "description": "No evidence of physical dependence potential. Like LSD, 1cP-MiPLA is not associated with withdrawal symptoms or compulsive physical need for the substance.[cite:pmid-35107059]"
265 }
266 },
267 "toxicity": {
268 "organ_toxicity": [],
269 "carcinogenicity": {
270 "level": "unknown",
271 "evidence": null,
272 "description": "No carcinogenicity studies have been conducted on 1cP-MiPLA."
273 },
274 "antibiotic_function": {
275 "level": "unknown",
276 "description": "No studies on antimicrobial properties."
277 }
278 },
279 "psychosis": {
280 "level": null,
281 "description": "May act as a potential trigger for psychotic episodes in individuals with underlying psychiatric conditions or family history of mental illness.[cite:pmid-35107059] Adverse psychological reactions including delusions become more likely at higher doses, though severe psychotic episodes requiring medical attention are uncommon with this substance alone."
282 },
283 "seizure": {
284 "level": null,
285 "description": "Seizures are reported rarely and are thought to mainly pose a risk in those who are genetically predisposed[cite:pmid-35981469], particularly when accompanied by physically taxing conditions such as dehydration, fatigue, or undernourishment. Risk is extrapolated from seizures reported following LSD use."
286 }
287 },
288 "history_culture": {
289 "content": "1cP-MiPLA is a novel synthetic lysergamide that first emerged on online research chemical markets around 2020.[cite:url-aipsin-com-562] The compound's origins remain somewhat unclear, with unverified reports attributing its initial synthesis to either Skyler Ulrich or a chemist or group operating under the name Gerstmann. It appeared alongside several other novel lysergamide derivatives, including 1cP-AL-LAD[cite:doi-10-1016-j-toxac-2022-06-295], as part of a wave of new designer psychedelics entering the grey market during this period.\n\nBy 2022, the compound had been identified in Japan[cite:doi-10-1007-s11419-023-00661-1], indicating its spread beyond initial Western markets. Like many contemporary research chemicals, 1cP-MiPLA was developed and distributed primarily through online vendors catering to the research chemical community[cite:url-aipsin-com-562], with limited formal scientific investigation into its properties beyond forensic identification studies.[cite:doi-10-1007-s11419-023-00661-1]\n",
290 "sections": []
291 },
292 "legality": {
293 "international": [],
294 "countries": {
295 "Austria": {
296 "status": "Controlled under analogue or structural rule",
297 "notes": "Canonical status: covered by NPSV Annex II no. 11 as a 9,10-didehydro-ergoline-8-carboxamide derivative. NPSV Annex III no. 11 provides illustrative lysergamide examples, but does not name 1cP-MiPLA specifically. The operative NPSG consequence supported here is the conduct- and intent-specific § 4(1) offense for producing, importing, exporting, transferring or supplying a covered NPS for another person's psychoactive use with intent to obtain an advantage (up to two years' imprisonment). These sources do not support an unqualified claim that mere possession or personal use is prohibited in every circumstance.",
298 "canonicalStatus": "analog_covered",
299 "instrument": "Neue-Psychoaktive-Substanzen-Verordnung (NPSV), Annex II no. 11; NPSG § 4(1) [cite:ris-bka-gv-at-neue-psychoaktive-substanzen-verordnung-npsv-annex-ii-no-11-npsg-4-1][cite:ris-bka-gv-at-neue-psychoaktive-substanzen-verordnung-npsv-annex-ii-no-11-npsg-4-1-37a749][cite:ris-bka-gv-at-neue-psychoaktive-substanzen-verordnung-npsv-annex-ii-no-11-npsg-4-1-66706f]"
300 },
301 "Germany": {
302 "status": "Illegal",
303 "notes": "Controlled substance as of July 2021.[cite:de-npsg-anlage1-ergolene-2021] Possession, production, and distribution are prohibited.[cite:de-npsg-para3-prohibitions]"
304 },
305 "Russia": {
306 "status": "Schedule I",
307 "notes": "Classified as a schedule I controlled substance under Russian drug control legislation.[cite:url-normativ-kontur-ru-document-moduleid-1-documentid-503195]"
308 },
309 "Switzerland": {
310 "status": "Controlled (Verzeichnis E)",
311 "notes": "Listed as a defined derivative of Lysergic Acid under Verzeichnis E point 263 of the controlled substances ordinance.[cite:ch-betmvv-edi-verzeichnis-e-263] Exempt when used for scientific or industrial purposes.[cite:ch-betmvv-edi-verzeichnis-e-263]"
312 },
313 "United States": {
314 "status": "Unscheduled",
315 "notes": "Not specifically scheduled under the Controlled Substances Act. However, may be prosecuted as an analogue of LSD under the Federal Analogue Act when intended for human consumption.[cite:us-21-usc-813-analogue-act]"
316 }
317 }
318 },
319 "source_citations": [
320 {
321 "name": "Isomer Design (TiHKAL/PiHKAL)",
322 "url": "https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=11316&name=1cP-MiPLA"
323 },
324 {
325 "name": "PsychonautWiki",
326 "url": "https://psychonautwiki.org/wiki/1cP-MiPLA"
327 },
328 {
329 "name": "TripSit: Drug Combinations Chart",
330 "url": "https://combo.tripsit.me/"
331 },
332 {
333 "name": "Wikipedia",
334 "url": "https://en.wikipedia.org/wiki/1cP-MiPLA"
335 }
336 ],
337 "citations": [
338 {
339 "name": "Halberstadt A.L. et al. Pharmacological characterization of novel lysergamides including MiPLA. Neuropharmacology (2020)",
340 "url": "https://pubmed.ncbi.nlm.nih.gov/32470368/"
341 },
342 {
343 "name": "Tanaka R. et al. Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products. Forensic Science International (2023)",
344 "url": "https://doi.org/10.1016/j.forsciint.2023.111594"
345 },
346 {
347 "name": "TripReport.net substance overview: 1cP-MiPLA",
348 "url": "https://tripreport.net/substances/1cP-MiPLA"
349 },
350 {
351 "name": "Wagmann L. et al. Analysis of LSD analogs (1cP-MiPLA, 1cP-LSD, etc.) in seized blotters. Forensic Toxicology (2021)",
352 "url": "https://link.springer.com/article/10.1007/s11419-021-00554-y"
353 }
354 ],
355 "references": [
356 {
357 "id": "ch-betmvv-edi-verzeichnis-e-263",
358 "type": "webpage",
359 "template": null,
360 "title": "Betäubungsmittelverzeichnisverordnung (BetmVV-EDI, SR 812.121.11), Anhang 5 Verzeichnis e, Ziff. 263 Lysergsäurederivate",
361 "authors": [],
362 "year": null,
363 "date": null,
364 "containerTitle": null,
365 "siteName": null,
366 "publisher": "Eidgenössisches Departement des Innern (EDI) / Bundesrecht (admin.ch)",
367 "volume": null,
368 "issue": null,
369 "pages": null,
370 "articleNumber": null,
371 "chapter": null,
372 "edition": null,
373 "series": null,
374 "location": null,
375 "institution": null,
376 "language": null,
377 "doi": null,
378 "pmid": null,
379 "isbn": null,
380 "url": "https://res.cloudinary.com/adminch/image/private/s--aGGgd8MH--/v1773719628/Bundespublikationen/812-121-11d.pdf",
381 "archiveUrl": null,
382 "archiveDate": null,
383 "accessedAt": null,
384 "sourceType": "unknown",
385 "quality": "high",
386 "discoverySource": "live_web_research",
387 "access": "open",
388 "supportStatus": "inspected",
389 "apaText": null
390 },
391 {
392 "id": "de-npsg-anlage1-ergolene-2021",
393 "type": "webpage",
394 "template": null,
395 "title": "Anlage NpSG — Änderung vom 03.07.2021 (Einführung Stoffgruppe 5.2 Δ9,10-Ergolene), Verordnung vom 28.06.2021 (BGBl. I S. 2231)",
396 "authors": [],
397 "year": null,
398 "date": null,
399 "containerTitle": null,
400 "siteName": null,
401 "publisher": "buzer.de (Gesetze-Änderungsdienst, Volltext mit BGBl.-Fundstellen)",
402 "volume": null,
403 "issue": null,
404 "pages": null,
405 "articleNumber": null,
406 "chapter": null,
407 "edition": null,
408 "series": null,
409 "location": null,
410 "institution": null,
411 "language": null,
412 "doi": null,
413 "pmid": null,
414 "isbn": null,
415 "url": "https://www.buzer.de/gesetz/12250/al149920-0.htm",
416 "archiveUrl": null,
417 "archiveDate": null,
418 "accessedAt": null,
419 "sourceType": "unknown",
420 "quality": "high",
421 "discoverySource": "live_web_research",
422 "access": "open",
423 "supportStatus": "inspected",
424 "apaText": null
425 },
426 {
427 "id": "de-npsg-para3-prohibitions",
428 "type": "webpage",
429 "template": null,
430 "title": "§ 3 NpSG — Unerlaubter Umgang mit neuen psychoaktiven Stoffen",
431 "authors": [],
432 "year": null,
433 "date": null,
434 "containerTitle": null,
435 "siteName": null,
436 "publisher": "Bundesministerium der Justiz",
437 "volume": null,
438 "issue": null,
439 "pages": null,
440 "articleNumber": null,
441 "chapter": null,
442 "edition": null,
443 "series": null,
444 "location": null,
445 "institution": null,
446 "language": null,
447 "doi": null,
448 "pmid": null,
449 "isbn": null,
450 "url": "https://www.gesetze-im-internet.de/npsg/__3.html",
451 "archiveUrl": null,
452 "archiveDate": null,
453 "accessedAt": null,
454 "sourceType": "unknown",
455 "quality": "high",
456 "discoverySource": "live_web_research",
457 "access": "open",
458 "supportStatus": "inspected",
459 "apaText": null
460 },
461 {
462 "id": "doi-10-1002-dta-2789",
463 "type": "journal_article",
464 "template": null,
465 "title": "Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)",
466 "authors": [
467 "Brandt SD",
468 "Kavanagh PV",
469 "Westphal F",
470 "Stratford A",
471 "Odland AU",
472 "Klein AK",
473 "Dowling G",
474 "Dempster NM",
475 "Wallach J",
476 "Passie T",
477 "Halberstadt AL"
478 ],
479 "year": 2020,
480 "date": null,
481 "containerTitle": "Drug Testing and Analysis",
482 "siteName": null,
483 "publisher": null,
484 "volume": "12",
485 "issue": "6",
486 "pages": "812-826",
487 "articleNumber": null,
488 "chapter": null,
489 "edition": null,
490 "series": null,
491 "location": null,
492 "institution": null,
493 "language": null,
494 "doi": "10.1002/dta.2789",
495 "pmid": "32180350",
496 "isbn": null,
497 "url": "https://pubmed.ncbi.nlm.nih.gov/32180350/",
498 "archiveUrl": null,
499 "archiveDate": null,
500 "accessedAt": null,
501 "sourceType": "primary_literature",
502 "quality": "high",
503 "discoverySource": "live_web_research",
504 "access": "abstract_only",
505 "supportStatus": "inspected",
506 "apaText": null
507 },
508 {
509 "id": "doi-10-1002-nrc-20023",
510 "type": "journal_article",
511 "template": "unknown",
512 "title": "10.1002/nrc.20023",
513 "authors": [],
514 "year": "2004",
515 "date": null,
516 "containerTitle": null,
517 "siteName": null,
518 "publisher": null,
519 "volume": null,
520 "issue": null,
521 "pages": null,
522 "articleNumber": null,
523 "chapter": null,
524 "edition": null,
525 "series": null,
526 "location": null,
527 "institution": null,
528 "language": null,
529 "doi": "10.1002/nrc.20023",
530 "pmid": null,
531 "isbn": null,
532 "url": "https://doi.org/10.1002/nrc.20023",
533 "archiveUrl": null,
534 "archiveDate": null,
535 "accessedAt": null,
536 "sourceType": "primary_literature",
537 "quality": "medium",
538 "discoverySource": "psychonautwiki_local_rendered_reference_section",
539 "access": "unknown",
540 "supportStatus": "discovery_only",
541 "apaText": null
542 },
543 {
544 "id": "doi-10-1007-bf03161089",
545 "type": "journal_article",
546 "template": "unknown",
547 "title": "Dose-independent occurrence of seizure with tramadol",
548 "authors": [],
549 "year": "2009",
550 "date": null,
551 "containerTitle": null,
552 "siteName": null,
553 "publisher": null,
554 "volume": null,
555 "issue": null,
556 "pages": null,
557 "articleNumber": null,
558 "chapter": null,
559 "edition": null,
560 "series": null,
561 "location": null,
562 "institution": null,
563 "language": null,
564 "doi": "10.1007/BF03161089",
565 "pmid": null,
566 "isbn": null,
567 "url": "https://doi.org/10.1007/BF03161089",
568 "archiveUrl": null,
569 "archiveDate": null,
570 "accessedAt": null,
571 "sourceType": "primary_literature",
572 "quality": "medium",
573 "discoverySource": "psychonautwiki_local_rendered_reference_section",
574 "access": "unknown",
575 "supportStatus": "discovery_only",
576 "apaText": null
577 },
578 {
579 "id": "doi-10-1007-s11419-023-00661-1",
580 "type": "journal_article",
581 "template": "cite_journal",
582 "title": "Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products",
583 "authors": [
584 "Rie Tanaka",
585 "Maiko Kawamura",
586 "Sakumi Mizutani",
587 "Ruri Kikura-Hanajiri"
588 ],
589 "year": null,
590 "date": "2023",
591 "containerTitle": "Forensic Toxicology",
592 "siteName": null,
593 "publisher": null,
594 "volume": "41",
595 "issue": "2",
596 "pages": "294–303",
597 "articleNumber": null,
598 "chapter": null,
599 "edition": null,
600 "series": null,
601 "location": null,
602 "institution": null,
603 "language": null,
604 "doi": "10.1007/s11419-023-00661-1",
605 "pmid": "36809464",
606 "isbn": null,
607 "url": "https://link.springer.com/content/pdf/10.1007/s11419-023-00661-1.pdf",
608 "archiveUrl": null,
609 "archiveDate": null,
610 "accessedAt": "26 July 2025",
611 "sourceType": "primary_literature",
612 "quality": "high",
613 "discoverySource": "worker_inspected",
614 "access": "open",
615 "supportStatus": "inspected",
616 "apaText": null
617 },
618 {
619 "id": "doi-10-1016-0014-2999-94",
620 "type": "journal_article",
621 "template": "unknown",
622 "title": "Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists",
623 "authors": [],
624 "year": "1994",
625 "date": null,
626 "containerTitle": null,
627 "siteName": null,
628 "publisher": null,
629 "volume": null,
630 "issue": null,
631 "pages": null,
632 "articleNumber": null,
633 "chapter": null,
634 "edition": null,
635 "series": null,
636 "location": null,
637 "institution": null,
638 "language": null,
639 "doi": "10.1016/0014-2999(94",
640 "pmid": null,
641 "isbn": null,
642 "url": "https://doi.org/10.1016/0014-2999(94",
643 "archiveUrl": null,
644 "archiveDate": null,
645 "accessedAt": null,
646 "sourceType": "primary_literature",
647 "quality": "medium",
648 "discoverySource": "psychonautwiki_local_rendered_reference_section",
649 "access": "unknown",
650 "supportStatus": "discovery_only",
651 "apaText": null
652 },
653 {
654 "id": "doi-10-1016-j-neuro-2007-04-005",
655 "type": "journal_article",
656 "template": "unknown",
657 "title": "Ecstasy induces apoptosis via 5-HT2A-receptor stimulation in cortical neurons",
658 "authors": [],
659 "year": "2007",
660 "date": null,
661 "containerTitle": null,
662 "siteName": null,
663 "publisher": null,
664 "volume": null,
665 "issue": null,
666 "pages": null,
667 "articleNumber": null,
668 "chapter": null,
669 "edition": null,
670 "series": null,
671 "location": null,
672 "institution": null,
673 "language": null,
674 "doi": "10.1016/j.neuro.2007.04.005",
675 "pmid": "17572501",
676 "isbn": null,
677 "url": "https://doi.org/10.1016/j.neuro.2007.04.005",
678 "archiveUrl": null,
679 "archiveDate": null,
680 "accessedAt": null,
681 "sourceType": "primary_literature",
682 "quality": "medium",
683 "discoverySource": "psychonautwiki_local_rendered_reference_section",
684 "access": "unknown",
685 "supportStatus": "discovery_only",
686 "apaText": null
687 },
688 {
689 "id": "doi-10-1016-j-toxac-2022-06-295",
690 "type": "journal_article",
691 "template": "cite_journal",
692 "title": "Analyses of LSD analogs in illegal products: The identification of 1cP-AL-LAD, 1cP-MIPLA and 1V-LSD",
693 "authors": [
694 "Rie Tanaka",
695 "Maiko Kawamura",
696 "Sakumi Mizutani",
697 "Ruri Kikura-Hanajiri"
698 ],
699 "year": null,
700 "date": "2022",
701 "containerTitle": "Toxicologie Analytique et Clinique",
702 "siteName": null,
703 "publisher": null,
704 "volume": "34",
705 "issue": "3",
706 "pages": "S171",
707 "articleNumber": null,
708 "chapter": null,
709 "edition": null,
710 "series": null,
711 "location": null,
712 "institution": null,
713 "language": null,
714 "doi": "10.1016/j.toxac.2022.06.295",
715 "pmid": null,
716 "isbn": null,
717 "url": "https://doi.org/10.1016/j.toxac.2022.06.295",
718 "archiveUrl": null,
719 "archiveDate": null,
720 "accessedAt": null,
721 "sourceType": "primary_literature",
722 "quality": "high",
723 "discoverySource": "worker_inspected",
724 "access": "abstract_only",
725 "supportStatus": "inspected",
726 "apaText": null
727 },
728 {
729 "id": "doi-10-1111-j-1755-5949-2008-00059-x",
730 "type": "journal_article",
731 "template": "unknown",
732 "title": "The Pharmacology of Lysergic Acid Diethylamide: A Review",
733 "authors": [],
734 "year": "2008",
735 "date": null,
736 "containerTitle": null,
737 "siteName": null,
738 "publisher": null,
739 "volume": null,
740 "issue": null,
741 "pages": null,
742 "articleNumber": null,
743 "chapter": null,
744 "edition": null,
745 "series": null,
746 "location": null,
747 "institution": null,
748 "language": null,
749 "doi": "10.1111/j.1755-5949.2008.00059.x",
750 "pmid": null,
751 "isbn": null,
752 "url": "https://doi.org/10.1111/j.1755-5949.2008.00059.x",
753 "archiveUrl": null,
754 "archiveDate": null,
755 "accessedAt": null,
756 "sourceType": "primary_literature",
757 "quality": "medium",
758 "discoverySource": "psychonautwiki_local_rendered_reference_section",
759 "access": "unknown",
760 "supportStatus": "discovery_only",
761 "apaText": null
762 },
763 {
764 "id": "pmid-26841800",
765 "type": "journal_article",
766 "template": null,
767 "title": "Psychedelics",
768 "authors": [
769 "Nichols DE"
770 ],
771 "year": 2016,
772 "date": null,
773 "containerTitle": "Pharmacological Reviews",
774 "siteName": null,
775 "publisher": null,
776 "volume": "68",
777 "issue": "2",
778 "pages": "264–355",
779 "articleNumber": null,
780 "chapter": null,
781 "edition": null,
782 "series": null,
783 "location": null,
784 "institution": null,
785 "language": null,
786 "doi": "10.1124/pr.115.011478",
787 "pmid": "26841800",
788 "isbn": null,
789 "url": "https://pubmed.ncbi.nlm.nih.gov/26841800/",
790 "archiveUrl": null,
791 "archiveDate": null,
792 "accessedAt": null,
793 "sourceType": "unknown",
794 "quality": "fallback",
795 "discoverySource": "existing_article_reference",
796 "access": "open",
797 "supportStatus": "inspected",
798 "apaText": null
799 },
800 {
801 "id": "pmid-35107059",
802 "type": "journal_article",
803 "template": null,
804 "title": "Adverse effects of psychedelics: From anecdotes and misinformation to systematic science",
805 "authors": [
806 "Schlag AK",
807 "Aday J",
808 "Salam I",
809 "Neill JC",
810 "Nutt DJ"
811 ],
812 "year": 2022,
813 "date": null,
814 "containerTitle": "Journal of Psychopharmacology",
815 "siteName": null,
816 "publisher": null,
817 "volume": "36",
818 "issue": "3",
819 "pages": "258–272",
820 "articleNumber": null,
821 "chapter": null,
822 "edition": null,
823 "series": null,
824 "location": null,
825 "institution": null,
826 "language": null,
827 "doi": "10.1177/02698811211069100",
828 "pmid": "35107059",
829 "isbn": null,
830 "url": "https://pubmed.ncbi.nlm.nih.gov/35107059/",
831 "archiveUrl": null,
832 "archiveDate": null,
833 "accessedAt": null,
834 "sourceType": "unknown",
835 "quality": "fallback",
836 "discoverySource": "existing_article_reference",
837 "access": "open",
838 "supportStatus": "inspected",
839 "apaText": null
840 },
841 {
842 "id": "pmid-35981469",
843 "type": "journal_article",
844 "template": null,
845 "title": "Prevalence and associations of classic psychedelic-related seizures in a population-based sample",
846 "authors": [
847 "Simonsson O",
848 "Goldberg SB",
849 "Chambers R",
850 "Osika W",
851 "Long DM",
852 "Hendricks PS"
853 ],
854 "year": 2022,
855 "date": null,
856 "containerTitle": "Drug and Alcohol Dependence",
857 "siteName": null,
858 "publisher": null,
859 "volume": "239",
860 "issue": null,
861 "pages": "109586",
862 "articleNumber": null,
863 "chapter": null,
864 "edition": null,
865 "series": null,
866 "location": null,
867 "institution": null,
868 "language": null,
869 "doi": "10.1016/j.drugalcdep.2022.109586",
870 "pmid": "35981469",
871 "isbn": null,
872 "url": "https://pubmed.ncbi.nlm.nih.gov/35981469/",
873 "archiveUrl": null,
874 "archiveDate": null,
875 "accessedAt": null,
876 "sourceType": "unknown",
877 "quality": "fallback",
878 "discoverySource": "existing_article_reference",
879 "access": "open",
880 "supportStatus": "inspected",
881 "apaText": null
882 },
883 {
884 "id": "url-admin-ch-5093-pdf",
885 "type": "webpage",
886 "template": "unknown",
887 "title": "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel,psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien: Änderung vom 2. November 2015",
888 "authors": [],
889 "year": "2015",
890 "date": null,
891 "containerTitle": null,
892 "siteName": null,
893 "publisher": null,
894 "volume": null,
895 "issue": null,
896 "pages": null,
897 "articleNumber": null,
898 "chapter": null,
899 "edition": null,
900 "series": null,
901 "location": null,
902 "institution": null,
903 "language": null,
904 "doi": null,
905 "pmid": null,
906 "isbn": null,
907 "url": "https://www.admin.ch/opc/de/official-compilation/2015/5093.pdf",
908 "archiveUrl": null,
909 "archiveDate": null,
910 "accessedAt": null,
911 "sourceType": "unknown",
912 "quality": "fallback",
913 "discoverySource": "psychonautwiki_local_rendered_reference_section",
914 "access": "unknown",
915 "supportStatus": "discovery_only",
916 "apaText": null
917 },
918 {
919 "id": "url-aipsin-com-562",
920 "type": "webpage",
921 "template": "cite_web",
922 "title": "1cP-MIPLA",
923 "authors": [],
924 "year": null,
925 "date": null,
926 "containerTitle": "АИПСИН",
927 "siteName": "АИПСИН",
928 "publisher": null,
929 "volume": null,
930 "issue": null,
931 "pages": null,
932 "articleNumber": null,
933 "chapter": null,
934 "edition": null,
935 "series": null,
936 "location": null,
937 "institution": null,
938 "language": null,
939 "doi": null,
940 "pmid": null,
941 "isbn": null,
942 "url": "https://aipsin.com/newsubstance/562/",
943 "archiveUrl": null,
944 "archiveDate": null,
945 "accessedAt": "26 July 2025",
946 "sourceType": "unknown",
947 "quality": "fallback",
948 "discoverySource": "worker_inspected",
949 "access": "open",
950 "supportStatus": "inspected",
951 "apaText": null
952 },
953 {
954 "id": "url-deadiversion-usdoj-gov-orangebook-pdf",
955 "type": "unknown",
956 "template": "unknown",
957 "title": "Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026)",
958 "authors": [],
959 "year": null,
960 "date": "January 2026",
961 "containerTitle": null,
962 "siteName": null,
963 "publisher": "U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division",
964 "volume": null,
965 "issue": null,
966 "pages": null,
967 "articleNumber": null,
968 "chapter": null,
969 "edition": null,
970 "series": null,
971 "location": null,
972 "institution": null,
973 "language": null,
974 "doi": null,
975 "pmid": null,
976 "isbn": null,
977 "url": "https://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf",
978 "archiveUrl": null,
979 "archiveDate": null,
980 "accessedAt": null,
981 "sourceType": "unknown",
982 "quality": "fallback",
983 "discoverySource": "wikipedia_reference_cache",
984 "access": "unknown",
985 "supportStatus": "discovery_only",
986 "apaText": null
987 },
988 {
989 "id": "url-gesetze-im-internet-de-npsg-bjnr261510016-html",
990 "type": "unknown",
991 "template": null,
992 "title": "Neue-psychoaktive-Stoffe-Gesetz (NpSG) — Anlage 1",
993 "authors": [],
994 "year": null,
995 "date": null,
996 "containerTitle": null,
997 "siteName": null,
998 "publisher": "Bundesministerium der Justiz",
999 "volume": null,
1000 "issue": null,
1001 "pages": null,
1002 "articleNumber": null,
1003 "chapter": null,
1004 "edition": null,
1005 "series": null,
1006 "location": null,
1007 "institution": null,
1008 "language": null,
1009 "doi": null,
1010 "pmid": null,
1011 "isbn": null,
1012 "url": "https://www.gesetze-im-internet.de/npsg/BJNR261510016.html",
1013 "archiveUrl": null,
1014 "archiveDate": null,
1015 "accessedAt": null,
1016 "sourceType": "unknown",
1017 "quality": "high",
1018 "discoverySource": null,
1019 "access": "open",
1020 "supportStatus": "inspected",
1021 "apaText": null
1022 },
1023 {
1024 "id": "url-normativ-kontur-ru-document-moduleid-1-documentid-503195",
1025 "type": "unknown",
1026 "template": null,
1027 "title": "Постановление Правительства РФ от 30.06.1998 N 681 — Перечень наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации (ред. от 11.06.2025)",
1028 "authors": [],
1029 "year": null,
1030 "date": null,
1031 "containerTitle": null,
1032 "siteName": null,
1033 "publisher": "Правительство Российской Федерации",
1034 "volume": null,
1035 "issue": null,
1036 "pages": null,
1037 "articleNumber": null,
1038 "chapter": null,
1039 "edition": null,
1040 "series": null,
1041 "location": null,
1042 "institution": null,
1043 "language": null,
1044 "doi": null,
1045 "pmid": null,
1046 "isbn": null,
1047 "url": "https://normativ.kontur.ru/document?moduleId=1&documentId=503195",
1048 "archiveUrl": null,
1049 "archiveDate": null,
1050 "accessedAt": null,
1051 "sourceType": "unknown",
1052 "quality": "high",
1053 "discoverySource": "existing_article_reference",
1054 "access": "open",
1055 "supportStatus": "inspected",
1056 "apaText": null
1057 },
1058 {
1059 "id": "us-21-usc-813-analogue-act",
1060 "type": "webpage",
1061 "template": null,
1062 "title": "21 U.S.C. § 813 — Treatment of controlled substance analogues (Federal Analogue Act)",
1063 "authors": [],
1064 "year": null,
1065 "date": null,
1066 "containerTitle": null,
1067 "siteName": null,
1068 "publisher": "Cornell Law School, Legal Information Institute (U.S. Code)",
1069 "volume": null,
1070 "issue": null,
1071 "pages": null,
1072 "articleNumber": null,
1073 "chapter": null,
1074 "edition": null,
1075 "series": null,
1076 "location": null,
1077 "institution": null,
1078 "language": null,
1079 "doi": null,
1080 "pmid": null,
1081 "isbn": null,
1082 "url": "https://www.law.cornell.edu/uscode/text/21/813",
1083 "archiveUrl": null,
1084 "archiveDate": null,
1085 "accessedAt": null,
1086 "sourceType": "unknown",
1087 "quality": "high",
1088 "discoverySource": "live_web_research",
1089 "access": "open",
1090 "supportStatus": "inspected",
1091 "apaText": null
1092 },
1093 {
1094 "id": "wiki-ref-name-tanaka-2022-ref-name-tanaka-2023-1cp-mipla-has-been-encountered",
1095 "type": "unknown",
1096 "template": "unknown",
1097 "title": "<ref name=\"Tanaka_2022\" /><ref name=\"Tanaka_2023\" /> 1cP-MiPLA has been encountered as a novel [[designer drug]] online<ref name=\"Aipsin\" /> and in [[Japan]].<ref name=\"Tanaka_2022",
1098 "authors": [],
1099 "year": null,
1100 "date": null,
1101 "containerTitle": null,
1102 "siteName": null,
1103 "publisher": null,
1104 "volume": null,
1105 "issue": null,
1106 "pages": null,
1107 "articleNumber": null,
1108 "chapter": null,
1109 "edition": null,
1110 "series": null,
1111 "location": null,
1112 "institution": null,
1113 "language": null,
1114 "doi": null,
1115 "pmid": null,
1116 "isbn": null,
1117 "url": null,
1118 "archiveUrl": null,
1119 "archiveDate": null,
1120 "accessedAt": null,
1121 "sourceType": "unknown",
1122 "quality": "fallback",
1123 "discoverySource": "wikipedia_reference_cache",
1124 "access": "unknown",
1125 "supportStatus": "discovery_only",
1126 "apaText": null
1127 },
1128 {
1129 "id": "ris-bka-gv-at-neue-psychoaktive-substanzen-verordnung-npsv-annex-ii-no-11-npsg-4-1",
1130 "type": "webpage",
1131 "template": "cite_web",
1132 "title": "Neue-Psychoaktive-Substanzen-Verordnung (NPSV), consolidated official text, version 27 August 2026",
1133 "authors": [],
1134 "siteName": "ris.bka.gv.at",
1135 "publisher": "ris.bka.gv.at",
1136 "url": "https://www.ris.bka.gv.at/GeltendeFassung/Bundesnormen/20007642/NPSV%2c%20Fassung%20vom%2027.08.2026.pdf",
1137 "sourceType": "unknown",
1138 "quality": "fallback",
1139 "access": "unknown",
1140 "supportStatus": "inspected"
1141 },
1142 {
1143 "id": "ris-bka-gv-at-neue-psychoaktive-substanzen-verordnung-npsv-annex-ii-no-11-npsg-4-1-37a749",
1144 "type": "webpage",
1145 "template": "cite_web",
1146 "title": "Neue-Psychoaktive-Substanzen-Verordnung, Anlage II (BGBl. II Nr. 106/2024)",
1147 "authors": [],
1148 "siteName": "ris.bka.gv.at",
1149 "publisher": "ris.bka.gv.at",
1150 "url": "https://www.ris.bka.gv.at/Dokumente/Bundesnormen/NOR40261441/II_106_2024_Anlage_II.pdf",
1151 "sourceType": "unknown",
1152 "quality": "fallback",
1153 "access": "unknown",
1154 "supportStatus": "inspected"
1155 },
1156 {
1157 "id": "ris-bka-gv-at-neue-psychoaktive-substanzen-verordnung-npsv-annex-ii-no-11-npsg-4-1-66706f",
1158 "type": "webpage",
1159 "template": "cite_web",
1160 "title": "Neue-Psychoaktive-Substanzen-Gesetz (NPSG), consolidated official text, version 27 August 2026",
1161 "authors": [],
1162 "siteName": "ris.bka.gv.at",
1163 "publisher": "ris.bka.gv.at",
1164 "url": "https://www.ris.bka.gv.at/GeltendeFassung/Bundesnormen/20007605/NPSG%2c%20Fassung%20vom%2027.08.2026.pdf",
1165 "sourceType": "unknown",
1166 "quality": "fallback",
1167 "access": "unknown",
1168 "supportStatus": "inspected"
1169 }
1170 ],
1171 "expert_reviewed": true
1172}
Everything dose.wiki writes, including its articles and the schema and normalization behind the dataset, is dedicated to the public domain under CC0. Reuse it freely, no attribution required. The site's code is MIT. Trip reports, the TripSit interaction data embedded in the dataset download, and reagent tests keep their own terms.
Founders & Contributors
Partners & Community
Contact & Feedback
Questions about dose.wiki, collaboration, legal or media inquiries, or takedown requests — email us directly. For everything else, the feedback form reaches the same editors.